Medicenna Therapeutics is a clinical-stage immunotherapy company developing engineered cytokines, called Superkines, designed to improve the specificity, function, and safety profile of unmodified interleukins. Medicenna owns diverse platforms licensed from Stanford University to develop a pipeline of Superkine candidates: interleukin-2 (IL-2), IL-4 and IL-13 super-agonists and antagonists. MDNA11, a potential best-in-class, next-generation IL-2 super agonist targeting solid tumors, is currently in a Phase 2 monotherapy dose expansion trial and expected to begin a Phase 2 pembrolizumab combination trial in the fourth quarter of 2023. Medicenna’s IL-4-empowered Superkine, bizaxofusp (MDNA55), has completed a Phase 2b trial for recurrent glioblastoma and holds FastTrack and Orphan Drug status from the U.S. Food and Drug Administration (FDA) and FDA/European Medicines Agency, respectively. Medicenna also creates Bifunctional SuperKine Immunotherapies (BiSKITs), which have demonstrated superior anti-tumor activity in preclinical studies, even in hard-to-treat ‘cold’ tumors. For more information, please visit https://www.medicenna.com/.
Company profile
Ticker
MDNAF, MDNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
MDNAF stock data
Latest filings (excl ownership)
AW
Withdrawal of amendment
22 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 24
F-3/A
Shelf registration (foreign) (amended)
16 Apr 24
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
16 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4 Apr 24
6-K
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
6 Mar 24
6-K
Interim condensed consolidated financial statements of
14 Feb 24
6-K
Current report (foreign)
13 Feb 24
Transcripts
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
26.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 4.07 bn |
Total shares | 18.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Merchant Fahar | 5.50 mm | $0.00 |
Hirschman Orin | 4.35 mm | $0.00 |
AIGH Capital Management | 4.34 mm | $2.09 bn |
Worth Venture Partners | 1.09 mm | $524.50 mm |
Hudson Bay Capital Management | 780.56 k | $373.89 mm |
DAFNA Capital Management | 660.00 k | $317.92 mm |
Verition Fund Management | 589.50 k | $282.37 mm |
Sigma Planning | 305.30 k | $147.06 mm |
Letko, Brosseau & Associates | 120.00 k | $57.80 mm |
RY Royal Bank Of Canada | 118.76 k | $57.00 mm |
Press releases
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
10 Apr 24
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
9 Apr 24
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
9 Apr 24
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
14 Feb 24
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
13 Feb 24